EP4460523A4 - METHOD FOR THE TREATMENT OF ASTHMA WITH ANTI-LIGHT ANTIBODIES - Google Patents

METHOD FOR THE TREATMENT OF ASTHMA WITH ANTI-LIGHT ANTIBODIES

Info

Publication number
EP4460523A4
EP4460523A4 EP23737702.3A EP23737702A EP4460523A4 EP 4460523 A4 EP4460523 A4 EP 4460523A4 EP 23737702 A EP23737702 A EP 23737702A EP 4460523 A4 EP4460523 A4 EP 4460523A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating asthma
light antibodies
antibodies
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23737702.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4460523A2 (en
Inventor
Garry A Neil
H Jeffrey Wilkins
Sheridan J Carrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avalo Therapeutics Inc
Original Assignee
Avalo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalo Therapeutics Inc filed Critical Avalo Therapeutics Inc
Publication of EP4460523A2 publication Critical patent/EP4460523A2/en
Publication of EP4460523A4 publication Critical patent/EP4460523A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP23737702.3A 2022-01-05 2023-01-04 METHOD FOR THE TREATMENT OF ASTHMA WITH ANTI-LIGHT ANTIBODIES Pending EP4460523A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263296786P 2022-01-05 2022-01-05
US202263396308P 2022-08-09 2022-08-09
PCT/US2023/060064 WO2023133389A2 (en) 2022-01-05 2023-01-04 Methods of treating asthma with anti-light antibodies

Publications (2)

Publication Number Publication Date
EP4460523A2 EP4460523A2 (en) 2024-11-13
EP4460523A4 true EP4460523A4 (en) 2025-12-17

Family

ID=87074254

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23737702.3A Pending EP4460523A4 (en) 2022-01-05 2023-01-04 METHOD FOR THE TREATMENT OF ASTHMA WITH ANTI-LIGHT ANTIBODIES

Country Status (6)

Country Link
US (1) US20250002598A1 (https=)
EP (1) EP4460523A4 (https=)
JP (1) JP2025501865A (https=)
AU (1) AU2023205910A1 (https=)
CA (1) CA3240327A1 (https=)
WO (1) WO2023133389A2 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051352A1 (en) * 2015-08-21 2017-02-23 The Children's Hospital Of Philadelphia Methods of Treating Autoimmune Conditions in Patients with Genetic Variations in DCR3 or in a DCR3 Network Gene
US20170058037A1 (en) * 2007-09-18 2017-03-02 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007290570C1 (en) * 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170058037A1 (en) * 2007-09-18 2017-03-02 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US20170051352A1 (en) * 2015-08-21 2017-02-23 The Children's Hospital Of Philadelphia Methods of Treating Autoimmune Conditions in Patients with Genetic Variations in DCR3 or in a DCR3 Network Gene

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGACHE IOANA: "Non-eosinophilic Asthma Endotypes", CURRENT TREATMENT OPTIONS IN ALLERGY, vol. 2, no. 3, 6 May 2015 (2015-05-06), pages 257 - 267, XP093331707, ISSN: 2196-3053, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1007/s40521-015-0052-2.pdf> DOI: 10.1007/s40521-015-0052-2 *
AVALO: "Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma", 26 June 2023 (2023-06-26), XP093331836, Retrieved from the Internet <URL:https://ir.avalotx.com/news-events-presentations/press-releases/detail/173/avalo-announces-topline-data-from-phase-2-peak-trial-for-avtx-002-quisovalimab-in-patients-with-non-eosinophilic-asthma> *
KATHERINE J. BAINES ET AL: "Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 133, no. 4, 1 April 2014 (2014-04-01), AMSTERDAM, NL, pages 997 - 1007, XP055286629, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2013.12.1091 *

Also Published As

Publication number Publication date
AU2023205910A1 (en) 2024-06-06
US20250002598A1 (en) 2025-01-02
CA3240327A1 (en) 2023-07-13
JP2025501865A (ja) 2025-01-24
EP4460523A2 (en) 2024-11-13
WO2023133389A2 (en) 2023-07-13
WO2023133389A3 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
MX2022006992A (es) Metodos para tratar los trastornos relacionados con il-4/il-13 identificados digitalmente.
SG11202106766SA (en) Acute treatment and rapid treatment of headache using anti-cgrp antibodies
EP4192581A4 (en) METHODS OF TREATING GOUT
HUE070287T2 (hu) Anti-PAR-2 ellenanyagok és eljárások alkalmazásukra
IL299339A (en) Antibodies and methods for treating claudin-related diseases
ZA202203272B (en) Anti-stem cell factor antibodies and methods of use thereof
SG11202107981VA (en) Immunoglobulin a antibodies and methods of production and use
EP4460523A4 (en) METHOD FOR THE TREATMENT OF ASTHMA WITH ANTI-LIGHT ANTIBODIES
EP4277925A4 (en) Multispecific antibodies and methods of use
IL319208A (en) Treating asthma with anti-interleukin-33 antibody
EP4316119A4 (en) METHOD AND APPARATUS FOR IMPROVED CANDIDATE ASSIGNMENT SCHEMES FOR EXTENDED PDCCH
IL315441A (en) Treatment methods for small cell lung cancer
HK40118693A (en) Methods of treating asthma with anti-light antibodies
IL307556A (en) Cancer treatment methods using antibodies against TIGIT
GB202006886D0 (en) Method of culturing algae
EP4262774A4 (en) METHODS FOR TREATING ACHINDROPLASIA
HK40129577A (en) Treatment of asthma with an anti-interleukin-33 antibody
SG11202108140SA (en) Anti-bag2 antibody and methods of treating cancer
GB202108596D0 (en) Methods of selectively reducing antibodies
IL321679A (en) Anti-ROR2 antibodies and methods of use
HK40093618A (en) Methods of treating gout
CA3273734A1 (en) Methods of treating cancer using anti-ddr1 antibodies
IL320671A (en) Anti-FGFR3 Antibodies and Antigen-Binding Fragments and Methods of Using Them
HK40061098A (en) Safe and effective method of treating psoriasis with anti-il-23 specific antibody
HK40073192A (en) Claudin18 antibodies and methods of treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240710

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40118693

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20251113

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20251107BHEP

Ipc: A61K 39/395 20060101ALI20251107BHEP

Ipc: A61P 11/06 20060101ALI20251107BHEP